Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|May 12, 2021

LifeLines: Finding Light

Author(s)Melissa Bernstein

Melissa Bernstein, founder of toy company Melissa & Doug, talks about accepting the self in totality and journeying inwards.

Melissa Bernstein shares insights based on her own experiences from her book, LifeLines, with Psychiatric Times^TM.

Melissa Bernstein is the chief creative officer of Melissa & Doug and the founder of LifeLines.com.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

TRD: Matching Patients to the Right Treatment

ByMichael E. Thase, MD

August 11th 2026

exercise

Effective Prescription of Exercise for the Treatment of Depression and Anxiety

ByPrerna Gait, MD

August 4th 2026

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD

ByGregory Sullivan, MD

July 30th 2026

TNX-102 SL in Major Depressive Disorder: Targeting Slow-Wave Sleep

TNX-102 SL in Major Depressive Disorder: Targeting Slow-Wave Sleep

ByGregory Sullivan, MD

July 29th 2026

AI brain

What Designing AI Taught Me About Why Psychiatrists Ignore It

ByCynthia Sin Nga Lam, MBBS, MRCPsych

July 28th 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Trending on Psychiatric Times

Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs

New CTx-1301 Data Affirms Pharmacokinetic Profile to Treat ADHD

New in Narcolepsy: Pharmacology Updates

Psychiatry and the Treatment of Stuttering: A Blossoming Partnership

New Consensus Guidelines Classify Stuttering as a Brain-Based Disorder